Morepen Laboratories (NSE:MOREPENLAB) Issuance of Debt: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
72 GF Score
Price ₹62.56
GF Value ₹50.12
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Morepen Laboratories Issuance of Debt?

Morepen Laboratories NSE:MOREPENLAB +0.43% 72 Issuance of Debt is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 72/100 and a GF Value™ of ₹50.12 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Morepen Laboratories's Issuance of Debt for the three months ended in Mar. 2026 was ₹0 Mil.

Morepen Laboratories's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Morepen Laboratories Issuance of Debt Related Terms

Morepen Laboratories Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Issuance of Debt Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.23 65.95 38.35 591.83 1,317.82

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:MOREPENLAB
72GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of ₹0 Mil mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Issuance of Debt of ₹0 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Morepen Laboratories and its competitors.
Is Morepen Laboratories' Issuance of Debt too high?
Morepen Laboratories' current Issuance of Debt is ₹0 Mil. Overall, Morepen Laboratories has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Issuance of Debt compare to ZTS and UTHR?
Morepen Laboratories' Issuance of Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Drug Manufacturers company?
A good Issuance of Debt depends on the Drug Manufacturers industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Morepen Laboratories and its competitors. Morepen Laboratories's current Issuance of Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹50.12, compared to a current price of ₹62.56 — trading 24.8% above its estimated fair value. The current Issuance of Debt is ₹0 Mil. Morepen Laboratories' overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Issuance of Debt is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹62.56 is trading 24.8% above its estimated GF Value™ of ₹50.12. GuruFocus considers Morepen Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:MOREPENLAB:

  • Issuance of Debt: ₹0 Mil
  • GF Value™: ₹50.12 vs. price of ₹62.56 (24.8% above fair value)
  • GF Score™: 72/100 with 9 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
72GF Score

Get the complete analysis for NSE:MOREPENLAB

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹62.56
Price
₹50.12
GF Value